Related Experiment Video

Updated: Apr 25, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K

Survival trends among patients with advanced renal cell carcinoma in the United States

Binay Kumar Shah1, Krishna Bilas Ghimire

  • 1Cancer Center and Blood Institute, St. Joseph Regional Medical Center, Lewiston, Idaho, USA.

Urologia Internationalis
|August 21, 2014
PubMed
Abstract

Insights

Targeted therapies for advanced renal cell carcinoma (RCC) have not improved survival rates in a population-based study. This research indicates no significant survival benefit from these agents in advanced RCC patients.

Area of Science:

  • Oncology
  • Epidemiology
  • Clinical Trials

Background:

  • Sorafenib, a targeted therapy for advanced renal cell carcinoma (RCC), was approved in December 2005.
  • Several targeted agents have since been approved for advanced RCC treatment.
  • This study assesses if these advancements improved survival in a population-based cohort.

Purpose of the Study:

  • To evaluate the survival benefit of targeted therapeutic agents in advanced renal cell carcinoma (RCC) patients.
  • To determine if survival improvements seen in clinical trials translate to a broader population.

Main Methods:

  • Analysis of the SEER 18 registry database (2001-2009).
  • Calculation of relative survival rates for advanced RCC patients across different time periods (2001-2005, 2006-2007, 2008-2009).
  • Evaluation of survival rates stratified by age (<65 and ≥65 years) and sex.

Main Results:

  • A total of 7,047 advanced RCC patients were analyzed from 2001-2009.
  • 1- and 3-year relative survival rates for 2001-2009 were 26.7±0.6% and 10.0±0.4%, respectively.
  • No significant difference in 1- or 3-year relative survival rates was observed for patients diagnosed in later periods (2006-2009) compared to 2001-2005.

Conclusions:

  • Population-based data indicate no significant improvement in relative survival rates for advanced RCC patients during the era of targeted agents.
  • The survival benefits observed in targeted therapy trials may not be fully realized in the general patient population.
  • Further research is needed to understand factors influencing survival outcomes in advanced RCC.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
857
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
785
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
625